Dyne Therapeutics (NASDAQ:DYN) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Dyne Therapeutics (NASDAQ:DYN) posted its quarterly earnings data on Monday. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02, Zacks reports.

Dyne Therapeutics Trading Up 1.3 %

Shares of NASDAQ:DYN opened at $43.64 on Wednesday. The firm has a 50 day simple moving average of $38.13 and a 200-day simple moving average of $30.47. Dyne Therapeutics has a twelve month low of $6.40 and a twelve month high of $45.46. The company has a market capitalization of $3.81 billion, a PE ratio of -10.99 and a beta of 1.07.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 10,163 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at $5,256,821.36. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, SVP Richard William Scalzo sold 1,590 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $30.23, for a total value of $48,065.70. Following the completion of the sale, the senior vice president now directly owns 115,105 shares of the company’s stock, valued at $3,479,624.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Susanna Gatti High sold 10,163 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now owns 148,792 shares in the company, valued at $5,256,821.36. The disclosure for this sale can be found here. Insiders have sold 202,133 shares of company stock valued at $6,500,387 in the last ninety days. Insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Jefferies Financial Group raised their price target on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, May 20th. JPMorgan Chase & Co. lifted their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. HC Wainwright boosted their target price on Dyne Therapeutics from $48.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley lifted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Piper Sandler raised their target price on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.89.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.